摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(4-bromophenoxy)butanenitrile

中文名称
——
中文别名
——
英文名称
4-(4-bromophenoxy)butanenitrile
英文别名
4-(4-bromophenoxy)butyronitrile
4-(4-bromophenoxy)butanenitrile化学式
CAS
——
化学式
C10H10BrNO
mdl
MFCD05832660
分子量
240.099
InChiKey
CZVKOBMHSGGZBN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    13
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    33
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] METHODS FOR TREATING NEUROLOGICAL SYMPTOMS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES<br/>[FR] MÉTHODES DE TRAITEMENT DE SYMPTÔMES NEUROLOGIQUES ASSOCIÉS À DES MALADIES LYSOSOMALES
    申请人:GENZYME CORP
    公开号:WO2021156769A1
    公开(公告)日:2021-08-12
    Methods are provided for treating or preventing neurological symptoms and disorders which are associated with, e.g., lysosomal storage diseases. The methods include enhancing neuronal connectivity within the brain of a subject, increasing brain tissue volume, or preventing or delaying loss of brain tissue volume in a subject. Also provided are methods for monitoring the progression or regression of a neurological disorder, or assessing the onset of a neurological disorder, associated with a lysosomal storage disease, in which brain tissue volume of the subject is measured.
    提供了用于治疗或预防与溶酶体贮积病等相关的神经症状和疾病的方法。这些方法包括增强受试者大脑内的神经连接、增加大脑组织体积,或者预防或延迟受试者大脑组织体积的丧失。还提供了用于监测神经疾病的进展或退化,或评估与溶酶体贮积病相关的神经疾病的发作的方法,其中测量了受试者的大脑组织体积。
  • [EN] METHODS FOR TREATING PROTEINOPATHIES<br/>[FR] PROCÉDÉS DE TRAITEMENT DE PROTÉINOPATHIES
    申请人:GENZYME CORP
    公开号:WO2016145046A1
    公开(公告)日:2016-09-15
    This disclosure relates to a method of treating a proteinopathy in a subject, the method comprising administering to the subject an effective amount of a quinuclidine compound. The disclosure also relates to a method of reducing, reversing or preventing the accumulation of protein aggregates in tissue of a subject diagnosed as having a proteinopathy, or being at risk of developing a proteinopathy, the method comprising administering to the subject an effective amount of a quinuclidine compound. Also disclosed is a pharmaceutical composition comprising a quinuclidine compound for use in said methods. The proteinopathy may be a synucleinopathy or a tauopathy, such as Parkinson's disease, Alzheimer's disease or dementia with Lewy bodies.
    这份披露涉及一种治疗受试者蛋白病的方法,该方法包括向受试者施用有效量的环丙胺化合物。该披露还涉及一种减少、逆转或预防被诊断为患有蛋白病或有患蛋白病风险的受试者组织中蛋白聚集物积累的方法,该方法包括向受试者施用有效量的环丙胺化合物。还披露了一种包含环丙胺化合物的药物组合物,用于上述方法。蛋白病可能是突触核蛋白病或tau蛋白病,如帕金森病、阿尔茨海默病或带有Lewy小体的痴呆症。
  • Derivatised molecules for mass spectrometry
    申请人:OXFORD GENE TECHNOLOGY IP LIMITED
    公开号:EP1506959A2
    公开(公告)日:2005-02-16
    Compounds of formula (IIa): are provided where: X is a group capable of being cleaved from the α-carbon atom to form an ion of formula (I') C is a carbon atom bearing a single positive charge or a single negative charge; The invention further provides compounds of formula (IIb): where: X is a counter-ion to C. The compounds of formula (IIa) and (IIb) may form ions of formula (I') by either cleaving the C-X bond between X and the α-carbon atoms in the case of the compounds of formula (IIa) or dissociating X in the case of compounds of formula (IIb).
    式(IIa)的化合物如下所示: 其中: X是一个能够从α-碳原子上被切断以形成式(I')离子的基团; C是带有单一正电荷或单一负电荷的碳原子; 本发明还提供了式(IIb)的化合物: 其中: X是C的对离子。 式(IIa)和(IIb)的化合物可以通过在式(IIa)的化合物中切断X和α-碳原子之间的C-X键,或在式(IIb)的化合物中解离X,形成式(I')离子。
  • Reactive trityl derivatives: stabilised carbocation mass-tags for life sciences applications
    作者:Alexey V. Ustinov、Vadim V. Shmanai、Kaajal Patel、Irina A. Stepanova、Igor A. Prokhorenko、Irina V. Astakhova、Andrei D. Malakhov、Mikhail V. Skorobogatyi、Pablo L. Bernad、Safraz Khan、Mona Shahgholi、Edwin M. Southern、Vladimir A. Korshun、Mikhail S. Shchepinov
    DOI:10.1039/b810600b
    日期:——
    The rational design of novel triarylmethyl (trityl)-based mass tags (MT) for mass-spectrometric (MS) applications is described. We propose a "pK(R+) rule" to correlate the stability of trityl carbocations with their MS performance: trityls with higher pK(R+) values ionise and desorb better. Trityl blocks were synthesised that have high pK(R+) values and are stable in conditions of MS analysis; these
    描述了用于质谱(MS)应用的新型基于三芳基甲基(三苯甲基)的质量标签(MT)的合理设计。我们提出了一个“ pK(R +)规则”,以将三苯甲基碳正离子的稳定性与其MS性能相关联:具有较高pK(R +)值的三苯甲基离子会更好地离子化和脱附。合成了具有高pK(R +)值且在MS分析条件下稳定的三苯甲基嵌段;这些MTs可以通过基质以及337 nm氮气激光照射而被电离。(13)C-Labelled标签已准备用于MS定量应用。此外,标签配备有多种官能团,允许在(生物)分子内与不同功能缀合,以增强后者的MS特性。研究了具有和不具有基质的模型聚阳离子三苯甲基化合物的MS行为,发现在(MA)LDI-TOF条件下聚三苯甲基簇总是带单电荷。制备了几种肽-三苯甲基偶联物,并且比较揭示了三苯甲基标签对MS中偶联物检测的有益作用。含有对甲氧基和二甲胺基团的三苯甲基化合物,以及a吨片段,在MS检测模型肽方面显示出可观的
  • Truce–Smiles rearrangement of substituted phenyl ethers
    作者:Joel R. Kosowan、Zemane W'Giorgis、Ravneet Grewal、Tabitha E. Wood
    DOI:10.1039/c5ob00812c
    日期:——
    ring activation by strong-electron withdrawing substituents in substrates for the intramolecular nucleophilic aromatic substitution reaction known as the Truce–Smiles rearrangement was examined. Preliminary mechanistic experiments support the SNAr mechanism, including 1H and 13C NMR spectra of a Meisenheimer intermediate formed in situ. The rearrangement was generally observed to be successful for substrates
    研究了分子内亲核芳族取代反应(称为Truce-Smiles重排)中底物中强电子吸收取代基对芳环活化的要求。初步的力学实验支持S N Ar机理,包括原位形成的Meisenheimer中间体的1 H和13 C NMR光谱。通常观察到重排对于具有强吸电子取代基(例如硝基,氰基和苯甲酰基官能团)的底物是成功的,但对于具有多个弱吸电子取代基(例如氯和溴官能团)的底物也是如此组。这些结果提供进一步的澄清的芳基取代基在这种类型的S的影响Ñ的Ar反应。另外,该调查还揭示了某些底物进行的一些串联环化和/或消除反应。
查看更多